Latest guidance given with Q3 FY2026 results, 29 Oct 2026
| Measure | Period | Guidance | As stated |
|---|---|---|---|
| Tax rate · Adjusted | FY2026 | 21% | GAAP projected effective tax rate 21% |
Source: the company's earnings release.
In its results release of 29 Oct 2026 (Q3 FY2026), Gilead Sciences gave 1 forecast in figures, among them tax rate (adjusted) of 21% for FY2026.
Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.
| Measure | Period | Guidance | As stated |
|---|---|---|---|
| Tax rate · Adjusted | FY2026 | 21% | GAAP projected effective tax rate 21% |
Source: the company's earnings release.
The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.
| Measure | Period | Last guidance | Revisions | Delivered | Result |
|---|---|---|---|---|---|
| EPS | FY2026 | −$3.25 to −$2.85 | Lowered once | — | To come |
| EPS · Adjusted | FY2026 | −$1.05 to −$0.65 | Given once | — | To come |
| Tax rate · Adjusted | FY2026 | 21% | Unchanged | — | To come |
| EPS · Adjusted | FY2025 | $8.05 to $8.25 | Raised twice | $8.15 | Within the range |
| EPS · Adjusted | FY2024 | $4.25 to $4.45 | Given once | $4.62 | Above the range |
Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.